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Cryptococcal meningitis (CCM) remains one of the leading causes of mortality among HIV
infected patients. Due to factors such as the severity of CCM pathology, the quality of life
(QOL) of patients post-treatment is likely to be poor. Few studies have reported on QOL of
CCM patients post treatment completion. We used data collected among patients in the
CryptoDex trial (ISRCTN59144167) to determine QOL and associated factors at week 10
and six months from treatment initiation.
Methodology
CryptoDex was a double-blind placebo-controlled trial of adjunctive dexamethasone in HIV
infected adults with CCM, conducted between 2013 and 2015 in six countries in Asia and
Africa. QOL was determined using the descriptive and Visual Analog Scales (VAS) of the
EuroQol Five-Dimension-Three-Level (EQ-5D-3L) tool. We derived index scores, and
described these and the VAS scores at 10 weeks and 6 months; and used linear regression
to determine the relationship between various characteristics and VAS scores at both time
points. VAS scores were interpreted as very good (81–100), good (51–80), normal (31–50)
and bad/very bad (0–30).
Results
Of 451 patients enrolled in the trial, 238 had QOL evaluations at week 10. At baseline, their
mean age (SD) was 35.2(8.5) years. The mean index scores (SD) were 0.785(0.2) and
0.619(0.4) among African and Asian patients respectively at week 10, and 0.879(0.2) and
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0.731(0.4) among African and Asian patients respectively at month six. The overall mean
VAS score (SD) at 10 weeks was 57.2 (29.7), increasing significantly to 72(27.4) at month
six (p<0.001). At week 10, higher VAS score was associated with greater weight (p = 0.007)
and being African (p<0.001), while lower VAS score was associated with positive yeast cul-
ture at day 14 (p = 0.026). At month six, higher VAS score remained associated with African
origin (p = 0.006) while lower VAS score was associated with positive yeast culture (p =
0.006). Lower VAS scores were associated with higher number of inpatient days at 10
weeks and 6 months (p = 0.003 and 0.002 respectively).
Conclusion
QOL was good among patients that had completed therapy for CCM, but below perfect.
Strategies to improve QOL among CCM survivors are required.
Author summary
In spite of the remarkable reduction in Cryptococcal meningitis (CCM) related morbidity
and mortality with increased use of antiretroviral therapy, incidence remains unaccept-
ably high especially in sub-Saharan Africa and Asia where more than 90% of the cases and
deaths occur.
Due to factors such as the severity of CCM pathology, the quality of life (QOL) of
patients post-treatment is also likely to be poor. Few studies have reported on QOL of
CCM patients post treatment completion. We used data collected among patients in the
CryptoDex trial (ISRCTN59144167) to determine self-perceived QOL and associated fac-
tors among 238 survivors at week 10 and 203 survivors at six months from treatment initi-
ation. We determined QOL using the descriptive and Visual Analog Scales (VAS) of the
EuroQol Five-Dimension-Three-Level (EQ-5D-3L) tool. We found that while self-per-
ceived QOL was only relatively good among this cohort of patients who had survived
through treatment for CCM, it continued to improve over the 6 months following diagno-
sis. Low weight at diagnosis, prolonged hospital admission, positive yeast culture at day
14/treatment completion, and being Asian were associated with lower QOL. QOL is an
important outcome that should be considered among HIV infected patients treated for
serious infections such as CCM.
Introduction
Cryptococcal meningitis (CCM) is one of the leading causes of mortality among HIV infected
patients, especially in sub-Saharan Africa and Asia. Mortality from CCM remains high, in
spite of a significant reduction in the incidence of opportunistic infections (OIs), resulting
from improvement in HIV management including early initiation of antiretroviral therapy
(ART) [1]. Between 2009 and 2014, the estimated global annual incidence and mortality due to
CCM reduced from 975,900 to 223,100 and 624,700 to 181,100 respectively [2,3]. While inci-
dence, prevalence, and mortality indices have been used widely to demonstrate the burden of
CCM amongst HIV infected patients, its effects on other important measures of health such as
quality of life (QOL) have not been adequately evaluated. Due to the advanced stage of AIDS
at which CCM occurs, severity of disease pathology, toxicity of antifungal medications and
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disease sequelae, the QOL post-treatment is likely to be poor. We previously showed that
patients with low QOL at treatment completion are more likely to die two years later than
those with higher QOL[4] (this analysis included some participants reported on in this paper,
particularly those from Uganda). Previous research has demonstrated that QOL measurements
amongst HIV infected patients should be done routinely [5–8], since improved QOL is one of
the ultimate goals of HIV management. We used data collected from patients enrolled in the
CryptoDex trial (PMID: 25391338, ISRCTN59144167) [9,10] to determine QOL at 10 weeks
and six months since treatment initiation and the factors associated with high or low QOL at
10 weeks and six months. We hypothesised that QOL would increase between 10 weeks since
treatment initiation and six months among patients enrolled in the CryptoDex trial.
Methodology
Ethics statement
Ethical approval was obtained from: OxTREC, Oxford, UK 25–12; Ministry of Health, Viet-
nam; Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; Ministry of Health Laos
039/NECHR; Faculty of Medicine, Universitas Indonesia, Indonesia 623/H2.F1/ETIK/2012;
Mahidol University, Thailand MUTM 2012-051-01; Institute for the Development of Human
Research Protections, Thailand 04CN; Uganda Council for Science and Technology HS1264;
National Drug Authority, Uganda 020/ESR/NDA/DID-01/2013; Ministry of Health, Malawi
#1077; Pharmacy, Medicines and Poisons Board, Malawi PMPB/CTRC/111/3105201354; Uni-
versity of Toronto, Canada 28199.
Written consent was obtained from all patients or their representatives.
Study design and setting
The CryptoDex trial was a double-blind placebo-controlled phase III trial of adjunctive dexa-
methasone in HIV infected adults with cryptococcal meningitis. The study was conducted
between 2013 and 2015 at thirteen sites in six countries in Asia and Africa (Vietnam, Thailand,
Indonesia, Laos, Uganda, and Malawi).
Subjects enrolled in the CryptoDex study and their management
Patients recruited in the CryptoDex study were 18 years and above, had HIV infection, a clini-
cal syndrome consistent with CCM, and microbiological confirmation of disease, as indicated
by one or more of the following test results: 1) positive India ink staining of cerebrospinal fluid
(CSF); 2) culture of Cryptococcus species from CSF or blood; or 3) cryptococcal antigen
detected in CSF on cryptococcal antigen lateral flow assay (IMMY). Exclusion criteria included
pregnancy, renal failure, gastrointestinal bleeding, having been treated with more than 7 days
of anticryptococcal antifungal therapy, and being on or requiring glucocorticoid therapy for
coexisting conditions. Informed consent was obtained from all patients or a next of kin where
a patient was not in position to consent. Eligible patients were randomised in a 1:1 ratio, strati-
fied by site, to receive either dexamethasone adjunctive therapy or placebo in a tapered dose
until 42 days post-randomisation. Details of other study procedures and investigations can be
found in the CryptoDex study protocol [11].
The treatment regimen included an induction phase with intravenous Amphotericin B (1
mg/kg/day) and oral Fluconazole 800mg daily for 14 days, followed by a continuation phase of
800mg daily fluconazole for eight weeks, and then a maintenance phase with oral fluconazole
200mg daily. This regimen was consistent with the WHO treatment recommendation for set-
tings where Flucytosine was not available at the time the trial was conducted [12].
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Patients were followed up in the study until six months after enrolment, with all study visits
conducted at the study clinics or in hospitals for patients under admission. At six months, par-
ticipants were exited and referred back to their HIV care clinics for continuation of HIV care.
Subjects included in this analysis
This QOL analysis includes patients who survived up to 10 weeks post-treatment initiation
when the first QOL assessment was performed. A second QOL assessment was done at month
six and therefore patients who had not died between 10 weeks and six months and were acces-
sible i.e., able to come to the clinics, are included in the six months analysis.
Variables and their measurement in the cryptodex study
Quality of life was measured using the EQ-5D-3L tool [13]. This tool gives a subjective mea-
sure for the QOL, which is in line with the definition of QOL by WHO. The WHO defines
QOL as an individuals’ perception of their position in the context of culture and value systems
in which they live and in relation to their goals, expectations, standards, and concerns [14].
The tool is a widely used measure of health status consisting of two parts. The first part (the
descriptive system) assesses health in five dimensions (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression). Each dimension has three levels of response (no
problems, some problems, extreme problems/not able to). This part of the EQ-5D-3L ques-
tionnaire provides a descriptive profile that can be used to generate a health state profile. For
example, a patient in health state 11233 would have no problems in mobility and self-care,
some problems with usual activities, severe/extreme pain/discomfort, and extreme anxiety or
depression. Each health state is assigned a summary index score based on societal preference
weights for the health state. Heath state index scores generally range from less than 0 (where 0
is a health state equivalent to death; negative values are valued as worse than death) to 1 (per-
fect health). Health state preferences can differ between countries. Where a value set is not
available for a country/region, the assessor can opt to select a value set for a country/region
considered to most closely approximate the country of interest [13]. We used the Thailand
value set for sites in Asia (Vietnam, Thailand, Indonesia and Laos) [15] and the Zimbabwe
value set for sites in Africa (Uganda and Malawi) [16]. The second part of the EQ-5D-3L ques-
tionnaire consists of a visual analog scale (VAS) on which the patient rates his/her self-per-
ceived health from 0 (the worst imaginable health) to 100 (the best imaginable health/perfect
health).
The tool was translated into the local languages and administered by a study doctor who
read the questions to the patient. Other details concerning its administration can be found in
the study protocol [11].
Data analysis
All data from the CryptoDex study was derived from the secure OUCRU proprietary CLiRES
trial database. Data were extracted into a Microsoft Access database for export to STATA (Col-
lege Station, TX, version 15.0). Categorical variables were summarised by frequencies and per-
centages, while continuous variables were summarised using means (standard deviations)
and/or medians (interquartile ranges).
A health profile was generated by continent and time points (i.e., week 10 and month six),
from which we derived a health state index score using the selected value sets for each region.
We then summarised the index scores by means, standard deviations (SD), and minimum and
maximum scores by continent at the different time points. VAS scores were interpreted as
very good (81–100), good (51–80), normal (31–50) and bad/very bad (0–30) [17]. T-tests were
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used to compare VAS scores between continents and to test for significant changes in VAS
scores and index scores at the different time points among different variables. We also com-
puted and presented percentages of categories under each of the five dimensions of the EQ-
5D-3L questionnaire.
We used linear regression to assess the impact of a number of variables on QOL measured
using the VAS scores at week 10 and month six including: demographic characteristics (age,
sex, and education measured as number of years in school); Glasgow Coma Score (GCS) conti-
nent, i.e. Asia or Africa; ART status, i.e. on or not on ART; time on ART; most recent CD4
count at enrolment; presence of convulsions; intervention arm, i.e., dexamethasone or placebo;
Number of inpatient days by week 10 and month six (i.e., including days of readmission after
the first hospitalisation), baseline CSF fungal burden, yeast culture at 14 days, and Number of
adverse events (neurological events, new AIDs defining illnesses, other adverse events, and
inflammatory immune reconstitution syndrome events).
This analysis was not repeated using index scores as two value sets (Thailand and Zimba-
bwe) were used, and sample sizes were too small to conduct separate analyses. Variables that
had a p-value of 0.2 and below at univariate analysis were included in a multivariable linear
regression model. Variables were retained in the multivariable model if their inclusion did not
make the model significantly worse at LRT p-value 0.05.
Results
Baseline characteristics
Fig 1 is a flow diagram showing the patients included in this analysis. Out of 823 patients
screened at the 13 sites globally, 451 were found eligible and randomized. One patient was sub-
sequently excluded because he never received the assigned study drug due to an administrative
error. Out of the remaining 450 patients, 251 (55.8%) survived to week 10 post-treatment initi-
ation, and 238 (94.8%) completed a QOL assessment and were included in our analysis. The
other 13 (5.2%) patients were not accessible for the quality of life assessment since they did not
come to the clinics. A comparison of baseline characteristics among the 238 participants
included in the analysis and the 213 not included is shown in S1 Table. At baseline, the mean
age (SD) of the 238 patients was 35.2 (8.5) years, and 101 (42.4%) were on ART. The median
CD4 count (IQR) was 30 (13, 71) cells/ml. Thirty (12.6%) patients reported a history of convul-
sions. Of the 238 patients, 113 (47.5%) had been randomised to receive dexamethasone
adjunctive therapy. The baseline characteristics are summarised in Table 1.
Adverse events
Four hundred and thirty-four adverse events were captured among these participants, includ-
ing 67 new neurological events, 93 new AIDs defining illnesses, 365 other adverse events, and
9 immune reconstitution syndrome events.
Quality of life assessment
Descriptive system and index scores. Health profile results for patients at both time
points are summarised in Table 2. There was no difference in the proportion of patients from
Africa or Asia rating themselves as having perfect health (i.e., profile 11111) at 10 weeks
(Africa: 40 of 124 (32.3%); Asia: 37 of 114 (32.5%)). At this time point, 4 Asian patients (3.5%)
rated themselves as having the worst health state possible i.e. 33333 compared with 1 African
patient (0.8%, p = 0.2). At month six, reported quality of life had increased in both African and
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Asian centres, with 58 of 104 (55.8%) Africans and 48 of 99 (48.5%) Asians rating themselves
as having perfect health (p = 0.2).
At week 10, the mean index scores (SD, range) were 0.785 (0.2, -0.145 to 1) and 0.619 (0.4,
-0.452 to 1) for African and Asian patients respectively, increasing significantly at month six,
to 0.879 (0.2, 0.341 to 1), p = 0.002 and 0.731 (0.4, -0.452 to 1), p = 0.052 for African and Asian
patients respectively.
EQ VAS scale results
The overall mean VAS score (SD) at 10 weeks was 57.2 (29.7), increasing significantly to 72
(27.4) at month six (p<0.001), both mean scores falling within category 51–80, i.e. “Good
QOL”. The mean score (SD) at 10 weeks was significantly higher among African patients than
Asian patients i.e., 65.7 (21.5) vs 47.5 (34.5), p<0.001. Similarly, the mean score (SD) at six
months was significantly higher among African patients compared to Asian patients i.e., 79
(17.7) vs 64.2 (33.4), p<0.001.
The mean (SD) VAS scores at 10 weeks among those that received dexamethasone and pla-
cebo were not statistically significantly different, i.e., 54.5 (30.4) and 59.4 (29), p = 0.22
respectively.
Fig 1. Flow diagram showing participants enrolled in CryptoDex trial who had quality of life evaluations done. �
Patients were not able to come to clinics to have QOL assessment.
https://doi.org/10.1371/journal.pntd.0008983.g001
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Similarly, there was no statistically significant difference in mean VAS score at month 6
among those that received dexamethasone and placebo i.e., 69.1 (28.7) and 74.2 (26.1),
p = 0.193, respectively.
Mean VAS and Index scores at week 10 and month six are represented in Fig 2. There was a
statistically significant increase in mean VAS between week 10 and month six on all variables
Table 1. Baseline characteristics of the patients that had QOL evaluation at 10 weeks.
Overall Africa Asia
Variable Level Frequency (%) Frequency (%) Frequency (%)
Gender (n = 238) Male 152(63.9) 71(57.3) 81(71.1)
Female 86(36.1) 53(42.7) 33(29.0)
Mean age (SD), (n = 238) 35.2(8.5) 34.9(8.7) 35.7(8.3)
Median CD4 (IQR), (n = 126)� 30(13, 71) 40(15, 104) 25(9, 51)
Years in school (n = 215)�� �7 107(49.8) 63(57.3) 44(41.9)
>7 108(50.2) 47(42.7) 61(58.1)
Glasgow coma Score (n = 238) 15 210(88.2) 107(86.3) 103(90.4)
<15 28(11.8) 17(13.7) 11(9.6)
Median Period known to have HIV in years (179) (IQR) 0.5(0.1, 2.9) 0.5(0.2, 2) 0.2(0.1, 1.9)
On ARVs (n = 238) No 137(57.6) 53 (42.7) 84(73.7)
Yes 101(42.4) 71(57.3) 30(26.3)
Confusion (n = 238) No 180(75.6) 83(66.9) 97(85.1)
Yes 58(24.4) 41(33.1) 17(14.9)
Mean Weight (SD) (n = 238) 52.1(10.1) 52.7(10.8) 51.5(9.3)
Convulsion (n = 238) No 208(87.4) 117(94.3) 91(79.8)
Yes 30(12.6) 7(5.7) 23(20.2)
Intervention (n = 238) Dexamethasone 113(47.5) 55(44.4) 58(50.9)
Placebo 125(52.5) 69(55.6) 56(49.1)
CSF Culture, CFU/ml (n = 227)��� <1000cfu/ml 78(34.4) 47(39.8) 31(28.4)
�1000cfu/ml 149(65.6) 71(60.2) 78(71.6)
�Pre-enrolment CD4s considered. CD4s were not repeated in the study. Some patients had no record of CD4 counts.
��Responses could not be got for some participants because of altered consciousness.
���Lumbar punctures were not successful in a few patients.
https://doi.org/10.1371/journal.pntd.0008983.t001
Table 2. Health profile scores for patients at week 10 and month six.





















AFRICA 1(no problems) 79(63.7) 84(80.8) 102(82.3) 99(95.2) 59(51.8) 72(69.2) 72(58.1) 75(72.1) 78(63.4) 79 (76)
2(some
problems)
39(31.5) 20(19.2) 14(11.3) 4(3.8) 35(30.7) 25(24.1) 47(37.9) 28(26.9) 37(30.1) 21(21.1)
3(extreme
problems)
6(4.8) 0 8(6.4) 1(1) 20(17.5) 7(6.7) 5(4) 1(1) 8(6.5) 3(2.9)
ASIA 1(no problems) 71(62.3) 72(72.7) 83(72.8) 85(85.9) 59(51.8) 68(68.7) 60(53.1) 61(61.6) 76(68.5) 69(70.4)
2(some
problems)
28(24.5) 22(22.2) 16(14) 8(8.1) 35(30.7) 20(20.2) 42(37.2) 33(33.3) 28(25.2) 22(22.5)
3(extreme
problems)
15(13.2) 5(5.1) 1 (13.2) 6(6) 20(17.5) 11(11.1) 11(9.7) 5(5.1) 7(6.3) 7(7.1)
Abbreviations: n, Number; %, percentage.
https://doi.org/10.1371/journal.pntd.0008983.t002
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including gender (16.0, p<0.001 among males; 13.5, p<0.001 among females), GCS at baseline
(14.4, p<0.001 among “GCS = 15”; 20.6, p<0.001 among “GCS<15”), confusion at baseline
(12.9, p<0.001 for “no confusion”; 21.6, p<0.001 for “confusion present”), Convulsions at
baseline (14, p<0.001 among “convulsions present”; 21, p<0.001 among “convulsions
absent”), intervention (13.9, p<0.001 for placebo; 16.6, p<0.001 for dexamethasone), CSF cul-
ture at baseline (15.2, p<0.001 for “<1000CFU/ml”; 16, p<0.001 among “�1000CFU/ml”),
and CSF culture at day 14(14.3, p<0.001 among “0 CFU/ml”; 16.3, p<0.001 for “>0CFU/ml”),
and continent (13, p<0.001 for Africa; 16.9, p<0.001 for Asia).
Factors associated with quality of life
Results from the univariate and multivariate analysis are summarised in Table 3. At week 10,
the baseline factors associated with higher VAS score at multivariate analysis were: greater
weight (regression coefficient 0.6, 95% CI: 0.2 to 1.1), p = 007; and being from Africa (regres-
sion coefficient 19.4, 95% CI: 9.8 to 29), p<0.001. Higher inpatient days by week 10 was associ-
ated with poorer VAS score (regression coefficient -0.6, 95% CI -1.1 to -0.2), p = 0.003.
Similarly, positive yeast culture at day 14 was associated with poorer VAS score (regression
coefficient -11.7, 95% CI -21.9 to -1.4), p = 0.026. There was no relationship between VAS
Fig 2. Mean VAS scores and Index scores at week 10 and 6 months after treatment initiation. Abbreviations: VAS, Visual analog scale; QoL, Quality of life.
https://doi.org/10.1371/journal.pntd.0008983.g002
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score at week 10 and presence of confusion, convulsions, CSF pressure, and fungal burden at
baseline.
At month six, African origin was associated with higher VAS score at multivariate analysis
(regression coefficient 15.6, 95% CI 4.5 to 26.7), p = 0.006, while positive yeast culture at day
14 was associated with poorer VAS score (regression coefficient -15.7, 95% CI -26.8 to -4.7),
p = 0.006. Again, higher inpatient days was associated with a reduced VAS score at 6 months
(regression coefficient -0.7, 95% CI -1.2 to 0.3, p = 0.002. There was no relationship between
VAS score at month six and presence of confusion, convulsions, CSF pressure, and fungal bur-
den at baseline.
Table 3. Quality of Life and associated factors at 10 weeks and 6 months.
WEEK 10 MONTH SIX
Univariate linear regression Multivariate linear
regression
Univariate linear regression Multivariate linear
regression
Variable Categories Reg. Coef. (95%
CI)
P Value Reg. Coef. (95%
CI)
P Value� Reg. Coef. (95%
CI)




Female 6(-2.1 to 14.1) 0.145 1.0(-8.7 to 10.8) 0.834 2.8(-5.2 to 10.8) 0.497
Age Cont. -0.1(-0.5 to 0.4) 0.852 -0.4(-0.9 to 0.2) 0.173 -0.2(-0.7 to 0.3) 0.558
Years in School �7
>7 -0.7(-9 to 7.6) 0.862 -2.2(-10.4 to 5.9) 0.588
Glasgow coma Score <15
15 7.2(-4.6 to 19.0) 0.230 1.8(-11.7 to 15.3) 0.795 3.7(-8.3 to 15.7) 0.547
ART at Baseline Yes
No -6.2(-14.0 to 1.6) 0.121 4(-5 to 12.9) 0.383 -7.7(-15.4 to 0.03) 0.051 2.9(-6.9 to 12.8) 0.557
Confusion Yes
No 7.2(-1.7 to 16.1) 0.114 5.2(-6 to 16.3) 0.362 -1.2(-10.1 to 7.6) 0.789
Weight Cont. 0.5(0.2 to 0.9) 0.005 0.6(0.2 to 1.1) 0.007 0.2(-0.2 to 0.5) 0.397
Convulsion Yes
No 11.9(0.3 to 23.4) 0.044 -2(-14.4 to 10.3) 0.745 5.5(-6.4 to 17.2) 0.366
Inpatient days by week 10 Cont. -0.7(-1.1 to -0.4) <0.001 -0.6(-1.1 to -0.2) 0.003 N/A N/A
Inpatient days by month
six
Cont. N/A N/A N/A N/A -0.5(-0.7 to -0.2) <0.001 -0.7(-1.2 to -0.3) 0.002
Intervention Dexa.
Placebo 4.9(-2.9 to 12.6) 0.220 0.6(-7.9 to 9.1) 0.886 5.1(-2.6 to 12.8) 0.193 2.7(6.9 to 12.2) 0.581
Continent Asia
Africa 18.2(10.8 to 25.6) <0.001 19.4(9.8 to 29) <0.001 14.8(7.4 to 22.2) <0.001 15.6(4.5 to 26.7) 0.006
CSF Culture, CFU/ml <1000
�1000 -6.5(-14.7 to 1.6) 0.116 0.9(-7.1 to 8.9) 0.821 -4.9(-12.9 to 3.1) 0.231 5.1(-5.4 to 15.6) 0.338
CSF culture day 14, CFU/
ml
0
>0 -17.7(-26.2 to -9.1) <0.001 -11.7(-21.9 to -1.4) 0.026 -15.9(-24.3 to -7.5) <0.001 -15.7(-26.8 to -4.7) 0.006
Adverse events None
1–3 -1.0(-10.5 to 8.5) 0.841 7.1(-3.2 to 17.5) 0.178 -3.1(-12.3 to 6.0) 0.498 10.1(1.2 to 21.3) 0.078
4+ -10.2(-22.0 to 1.6) 0.09 11.9(-2.9 to 26.6) 0.116 -10(-22.2 to 2.2) 0.107 17.6(-2.1 to 37.3) 0.079
Abbreviations: ART, Antiretroviral therapy; CI, Confidence interval; Reg, Regression; Coef, Coefficient; Cont. Continuous variable; N/A, not applicable; Dexa,
Dexamethasone; CFU/ml, Colony forming units per millilitre.
� Only variables with a P Value <0.2 in the univariate analysis were used in the multivariable linear regression model.
https://doi.org/10.1371/journal.pntd.0008983.t003
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Discussion
HIV-associated CCM is an extremely debilitating disease associated with high mortality.
Affected patients present with advanced HIV disease and considerable immunosuppression.
While the disease itself is associated with significant risks of sequelae including neurological
deficits, the treatment as well, of which amphotericin is the backbone, is also associated with
significant toxicities [18,19]. All these factors have the potential to reduce the QOL among
patients who survive up to treatment completion.
We were pleased to see that many patients reported relatively good self-perceived QOL fol-
lowing completion of treatment for CCM, and that this tended to improve thereafter through
the 6 months following diagnosis. However, given the nature of the disease and its treatment,
it is perhaps not surprising that very few patients reported ‘very good’ or ‘perfect’ health. We
did not assess QOL at study entry in the CryptoDex trial and thus could not measure improve-
ment directly attributable to antifungal treatment. However, we found that patients reported
significant improvements in QOL between 10 weeks and six months after diagnosis, measured
both with the descriptive and VAS scales. These continuing improvements in QOL are likely
due to multiple factors. These may include gradual improvement due to neurological recovery,
better engagement with health services, and the use of antiretroviral drugs. A previous study
identified that patients with stage 3 and 4 HIV disease had significant improvements in QOL
after ART initiation [5].
It has been shown previously that different antifungal combinations can be associated with
long term (6 month) differences in survival [20]. Therefore, while some of the improvement in
QOL seen in our patients, who all received the same antifungal treatment, may be due to the
factors we described above, developing more effective induction and consolidation therapy for
CCM is likely to yield further improvements in QOL.
We consider QOL an important health parameter to measure since better scores have been
shown to correlate with long term survival [4,21]. In our study, we used the EQ-5D-3L tool.
This has the advantages of simplicity and ease of administration including amongst very sick
patients, as well as ease of scoring and interpretation. While it has not been used previously in
many studies of CCM patients, our work shows that it can identify changes in QOL over time
following treatment of CCM. As such, it has the potential to identify patients who may benefit
from increased follow-up during the recovery process–further studies are needed. Identifying
such patients could help with distribution of scarce resources and ensure the best possible out-
comes for all patients.
We found that prolonged admission by week 10 and month 6 were associated with lower
QOL measured using the VAS at week 10 and month six. This is not surprising—patients
admitted for longer periods were likely more ill at baseline. A similar finding was reported in a
study done by Nafteux and colleagues in Belgium [22].
We were surprised to see that patients from African countries in the CryptoDex trial rated
themselves to have better QOL at week 10 and six months than did Asian patients. This effect
was seen with both the descriptive scale and VAS. This effect remained apparent in the
adjusted model. We suggest that this is probably a societal perceptual variation rather than an
indication of impact of disease. It may also be argued that the resilience developed by patients
in the African setting may influence their opinion about ill health. They may not eventually
perceive as equally bad ill health situations suffered as their Asian counterparts.
We found that higher weight was associated with higher VAS at week 10. The most likely
explanation here is that low weight is correlated with more severe disease [23].
We also found that patients who had positive yeast culture at day 14, which also corre-
sponded to the day of completion of Amphotericin therapy, had poorer quality of life at week
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10 and month six. Research had previously shown that positive CSF culture at day 14 of
Amphotericin was associated with poorer longer term outcomes including mortality and
relapse [24–26]. However, Rolfes and colleagues demonstrated that these poor outcomes were
prevented if 800mg of Fluconazole was used in the consolidation phase of treatment [27]. Our
finding that positive CSF culture is associated with poor QoL even when Fluconazole was used
at this dose deserves serious consideration.
Unlike a previous study from Uganda amongst HIV patients that found that male gender
was associated with better quality of life, we did not identify a difference between males and
females in terms of QOL following treatment for CCM [28].
Our analysis has some limitations. First, we used a subjective measure of QOL, which may
not be an absolute indication of the QOL of an individual. Naturally, optimistic people may
rate their health status higher than pessimistic ones. However, the WHO recommends that
QOL tools should measure from the subjective viewpoint since the patient’s experience is
more relevant than the assessment of an objective observer [29]. Second, we used health index
scores derived from models of countries that we assumed were similar to our own, since mod-
els do not exist for all the countries in our study. Use of validated index scores from the actual
countries that participated in CryptoDex could conceivably result in different outcomes. How-
ever, we think this is unlikely because we measured QOL at two time points and found
improvement over time. QOL was not assessed at baseline in the CryptoDex trial. This would
have been very informative since it would have enabled determination of the impact of treat-
ment on QOL as well as a comparison of differences in QOL for those that got dexamethasone
and those that did not. It would be interesting to determine the effect of some other factors
that were not measured in this study such as one’s perception of their HIV disease and the
presence or lack of social support.
The current doses of amphotericin, which clearly have the greatest antifungal effect, may in
fact be resulting in patient harm because of associated toxicities [30]. These toxicities may con-
tribute to lowering the quality of life of patients. QOL measurements among survivors could
help in parsing such data, while we wait for more effective and tolerable novel treatments to be
developed. Patients with attributes associated with poor quality of life identified here such as
low weight and positive yeast culture at day 14 need special consideration. Useful interventions
may include nutritional support and using culture results to inform discontinuation of ther-
apy. Culture and sensitivity may also rule out possibility of resistance to drugs. Simple inter-
ventions such as counselling may help patients deal with issues such as anxiety. This may be
supplemented by adherence counselling since CCM among patients on long-term ART is
often a marker of treatment failure, often due to poor adherence. Going forward, we also rec-
ommend that QOL assessment are incorporated in the evaluation of patients with cryptococcal
meningitis. The EuroQol Five-Dimension-Three-Level (EQ-5D-3L) tool used in this study
and other tools such as the WHO’s WHOQOL-100 [29] may be appropriately used to generate
useful data on quality of life. Qualitative QOL assessments may also provide useful information
that could inform interventions.
Conclusion
While self-perceived QOL was only relatively good among this cohort of patients who had sur-
vived through treatment for CCM, it continued to improve over the 6 months following diag-
nosis. Low weight at diagnosis, prolonged hospital admission, being Asian, and positive yeast
culture at day 14 were associated with lower self-perceived QOL. QOL is an important out-
come that should be considered among HIV infected patients treated for serious infections
such as CCM.
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